Holen Sie sich die Stockscreener-App
2.62
5.22%
0.13
Schlusskurs vom Vortag:
$2.49
Offen:
$2.47
24-Stunden-Volumen:
372.48K
Relative Volume:
0.48
Marktkapitalisierung:
$82.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.9424
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
+14.91%
1M Leistung:
+29.06%
6M Leistung:
+104.69%
1J Leistung:
-61.81%
1-Tages-Spanne:
$2.44
$2.66
1-Wochen-Bereich:
$2.25
$2.66
52-Wochen-Spanne:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.62 | 78.57M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Holdings of Acrivon Therapeutics Inc (ACRV) are aligned with the stars - Setenews
Volume Report: How Acrivon Therapeutics Inc stock reacts to bond yields2025 Historical Comparison & Growth-Oriented Investment Plans - BỘ NỘI VỤ
What drives Acrivon Therapeutics Inc stock priceTrendline Breakouts & Low Cost Capital Growth - earlytimes.in
SBI Cards and Payment Services Limited Stages Intraday Comeback Trend Change - earlytimes.in
How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser
ACRV SEC FilingsAcrivon Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - Setenews
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Insider Monkey
Investors in cash trouble should check out Acrivon Therapeutics Inc (ACRV) - Setenews
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics' (ACRV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Chmn Blume-Jensen Surrenders 19,904 Of Acrivon Therapeutics Inc [ACRV] - TradingView
Citadel Advisors LLC Acquires Additional Shares in Acrivon Therapeutics Inc - GuruFocus
ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target - GuruFocus
HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments - TipRanks
Acrivon insiders report RSU tax withholding, 2.05M shares held - Stock Titan
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - MarketBeat
Will Acrivon Therapeutics Inc. stock see PE expansionWeekly Trade Recap & High Accuracy Trade Alerts - newser.com
Research Analysts Issue Forecasts for ACRV FY2025 Earnings - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00 - Defense World
There is no way Acrivon Therapeutics Inc (ACRV) can keep these numbers up - Setenews
Acrivon Therapeutics Form 4: COO tax withholding on 613 RSU shares - Stock Titan
Acrivon Therapeutics stock rating reiterated by Citizens with $13 target - Investing.com Nigeria
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics Narrows Losses And Draws Analyst Support - Finimize
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements - TipRanks
Acrivon Therapeutics Shrinks Losses And Draws Analyst Optimism - Finimize
Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA) - The Globe and Mail
Is Acrivon Therapeutics Inc. stock supported by strong cash flowsMarket Trend Report & Community Verified Watchlist Alerts - newser.com
Acrivon Therapeutics Reports Q3 2025 Financial Results - TipRanks
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):